| 共同演者 |
Korenaga Masaaki（The Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine（NCGM）, Japan）, Matsui Teppei（The Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine（NCGM）, Japan）, Aoki Yoshihiko（The Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine（NCGM）, Japan）, Imamura Masatoshi（The Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine（NCGM）, Japan）, Murata Kazumoto（The Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine（NCGM）, Japan）, Nishida Nao（The Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine（NCGM）, Japan）, Sugiyama Masaya（The Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine（NCGM）, Japan）, Masaki Naohiko（The Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine（NCGM）, Japan）, Mizokami Masashi（The Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine（NCGM）, Japan） |
| 抄録 |
Background and Aim：Long-term, low-dose Peg-IFN administration has been shown to reduce the incidence of hepatocellular carcinoma in patients with liver cirrhosis infected with HCV. The aim of the study was to investigate whether IL28B single nucleotide polymorphisms（SNPs）was interacts with the efficiency of low-dose IFN and IFN could restore iron metabolic disorder. Methods：Twenty-four patients with HCV-related advanced fibrosis who did not achieve viral elimination after IFN therapy were allocated to either receive 90 ug of Peg-IFN-α2a, once every two weeks（n=14）or were followed-up without treatment（n=10）. IL28B SNPs（rs8099917）were investigated in patients with low-dose IFN. Serum levels of ALT, dROM, BAP, AFP, ferritin, and hepcidin were assessed at 0, 24, and 48 weeks after the observation. Results：At 48 weeks after initiating low-dose IFN, as compared to before treatment, the level of ALT in major alleles for IL28B SNPs tended to be lower than those in non-major alleles. However, there was no difference in the decreasing of AFP levels between major alleles and non-major alleles. The ratio of hepcidin to ferritin increased（P＜0.05）and antioxidant status（BAP/dROM）in the low-dose IFN group tended to be higher at 48 weeks Conclusions：Decreasing of serum AFP in low-dose IFN was showed in patients with non-interferon sensitive IL28B SNPs. Moreover, low-dose IFN improved the iron metabolic disorder in patients with HCV infection and possibly reduced oxidative stress. |
